Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL17632298 | 0.98 | ACHE (0.48) | ACHELMNANPSR1L3MBTL1CHKA | |
| SCHEMBL25848023 | 0.72 | LMNA (0.47) | ACHELMNANPSR1L3MBTL1CHKA | |
| SCHEMBL6263179 | 0.72 | CHKA (0.68) | LMNACHKAALDH1A1HTTSMN1; SMN2 | |
| Bromide SCHEMBL463578 | 0.72 | CHKA (0.43) | ACHELMNANPSR1L3MBTL1CHKA | |
| Bromide SCHEMBL463579 | 0.72 | CHKA (0.43) | ACHELMNANPSR1L3MBTL1CHKA | |
| Hydrochloric Acid SCHEMBL21061013 | 0.71 | CHKA (0.66) | LMNACHKAALDH1A1HTTSMN1; SMN2 | |
| Bromide SCHEMBL6263418 | 0.71 | CHKA (0.71) | ACHELMNACHKAALDH1A1HTT | |
| SCHEMBL5304924 | 0.70 | CHKA (0.49) | ACHELMNANPSR1L3MBTL1CHKA | |
| SCHEMBL10692064 | 0.70 | CHKA (0.57) | ACHELMNACHKAALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL11483900 | 0.69 | LMNA (0.51) | ACHELMNANPSR1L3MBTL1CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308557-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117321046-A | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230257363-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CERECOR INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022198112-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20170369469-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CERECOR, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| WO-2016100349-A2 | BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016049048-A1 | TREATMENT OF ANXIETY DISORDERS AND AUTISM SPECTRUM DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-31 | — | — | WO | disclosed |
| US-20080086006-A1 | Process for Making Substituted Piperidines | MERCK SHARP & DOHME CORP. | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369469-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | BDNF, CYP2D6, CYP11B1 | ACHE 669/4885LMNA 1584/4885NPSR1 386/4885 |
| US-20080086006-A1 | Process for Making Substituted Piperidines | ITPA, PAICS, PPIP5K2 | ACHE 2059/4885LMNA 3875/4885NPSR1 1837/4885 |
| US-20230257363-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | BDNF, CYP2D6, CYP11B1 | ACHE 669/4885LMNA 1584/4885NPSR1 386/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | ACHE 2086/4885LMNA 2029/4885NPSR1 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.